A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 2, 2008, Pages 275-281

  Kato, Takeshi ^a,b   Mishima, Hideyuki ^b   Ikenaga, Masakazu ^b   Murata, Kouhei ^b   Ishida, Hideyuki ^b   Fukunaga, Mutsumi ^b   Ota, Hirofumi ^b   Tominaga, Shusei ^b   Ohnishi, Tadashi ^b   Amano, Masahiro ^b   Ikeda, Kimimasa ^b   Ikeda, Masataka ^b,c   Sekimoto, Mitsugu ^b,c   Sakamoto, Junichi ^d   Monden, Morito ^b,c  

^a Minoh City Hospital   (Japan)

^b Multicenter Clinical Study Group of Osaka   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Combination chemotherapy; Doxifluridine; Irinotecan; Phase II clinical trials

Indexed keywords

CAPECITABINE; DOXIFLURIDINE; IRINOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANALYTIC METHOD; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EPIGASTRIC PAIN; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLOXURIDINE; FLUOROURACIL; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SAMPLE SIZE; SURVIVAL ANALYSIS;

EID: 36348939845     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0471-2     Document Type: Article

References (24)

1. Advanced Colorectal Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10:896-903
2. Borner MM, Schoffski P, de Wit R et al (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38:349-358
3. Borner MM, Bernhard J, Dietrich D et al (2005) A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 16:282-288
4. Cassidy J, Tabernero J, Twelves C et al (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084-2091
5. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
6. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047
7. Fuchs C, Marshall J, Mitchell E et al (2006) A randmized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). J Clin Oncol Proc ASCO 24:18s
8. Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147
9. Grothey A, Jordan K, Kellner O et al (2004) Capecitabine/irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: results of a randomized phase II study. J Clin Oncol Proc ASCO 22:14s
10. Heidelberger C, Chaudhuri NK, Danneberg P et al (1957) Fluorinated pyrimidines: anew class of tumor-inhibitory compounds. Nature 179:663
11. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama HB (1980) Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5- fluorouridine. Gann 71:112-123
12. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H (1983) Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull (Tokyo) 31:175-178
13. Ledermann JA, Leonard P, Seymour M (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:145-146
14. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115
15. Meta-Analysis Group in Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537-3541
16. Mishima H, Kato T, Yanagisawa M et al (2005) Sequential treatment with irinotecan and doxifluridine: Optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. Chemotherapy 51:32-39
17. Niitani H, Kimura K, Saito T et al (1985) Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) on patients with malignant cancer: Multi-institutional cooperative study (in Japanese). Jpn J Cancer Chemother 12:2044-2051
18. Ota K (1988) Multicentre cooperative phase II study of 5'-deoxy-5-fluorouridine in the treatment of colorectal cancer. J Int Med Res 16(suppl 2):19B-20B
19. Rea DW, Nortier JWR, Ten Bokkel Huinink WW et al (2005) A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16:1123-1132
20. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801-3807
21. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914
22. Shimada Y, Yoshino M, Wakui A et al (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913
23. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237
24. Van Cutsem E, Hoff PM, Harper P et al (2004) Oral capecitabine vs intravenous 5-floorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90:1190-7